JT
Yes. And we continue to look at those, and as we're still in the first year of launch of VASCEPA in United States, we hesitated to dilute the sales effects of what we're doing by any other product, even though some products could be significant, but by I think say by definition, they're not going to be the multibillion dollar opportunities that is VASCEPA. We're regularly approached by companies looking forward us to potentially promote or copromote their product. That's happened in United States. Since we announced we're going in Europe, we've got a whole another wave of countries -- or companies that have approached us about their products, some for global rights, some for European rights.
VASCEPA is a big opportunity globally. We want to make sure we get VASCEPA right. But, if appropriate opportunity presents themselves for fair value, we’re certainly open to those. I just don't want to do a deal just for the sake of doing a deal, particularly given the enormity of the VASCEPA. I would I guess, say, you got big pharma that has this primary care sales force, but they’re generally looking for products that are multiple billions in size that we think that there's various products out there that could be hundreds of millions in revenues that we could make a lot of money off of. That might be a little too small for big pharma, but might fit well with our sales force. But right now, our priority is growing scripts, getting approval and getting approval in Europe and getting launched there. But we'll keep looking in. But does it make sense? Yes, it does make sense.
Yes. And we continue to look at those, and as we're still in the first year of launch of VASCEPA in United States, we hesitated to dilute the sales effects of what we're doing by any other product, even though some products could be significant, but by I think say by definition, they're not going to be the multibillion dollar opportunities that is VASCEPA. We're regularly approached by companies looking forward us to potentially promote or copromote their product. That's happened in United States. Since we announced we're going in Europe, we've got a whole another wave of countries -- or companies that have approached us about their products, some for global rights, some for European rights.
VASCEPA is a big opportunity globally. We want to make sure we get VASCEPA right. But, if appropriate opportunity presents themselves for fair value, we’re certainly open to those. I just don't want to do a deal just for the sake of doing a deal, particularly given the enormity of the VASCEPA. I would I guess, say, you got big pharma that has this primary care sales force, but they’re generally looking for products that are multiple billions in size that we think that there's various products out there that could be hundreds of millions in revenues that we could make a lot of money off of. That might be a little too small for big pharma, but might fit well with our sales force. But right now, our priority is growing scripts, getting approval and getting approval in Europe and getting launched there. But we'll keep looking in. But does it make sense? Yes, it does make sense.